{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:49:19Z","timestamp":1791294559993,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.ejphar.2016.02.053","type":"journal-article","created":{"date-parts":[[2016,2,27]],"date-time":"2016-02-27T12:22:29Z","timestamp":1456575749000},"page":"8-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Treatments for post-menopausal osteoporotic women, what\u2019s new? How can we manage long-term treatment?"],"prefix":"10.1016","volume":"779","author":[{"given":"Soledad","family":"Herrero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda","family":"Pico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2016.02.053_bib1","unstructured":"AEMPS, 2014. Drug Description, (drug safety). \u3008http:\/\/aemps.gob.es\u3009 (risk communications Ref 2009\/10, last accesed on 13.10.14)."},{"key":"10.1016\/j.ejphar.2016.02.053_bib2","unstructured":"American College of Rheumatology, 2014. Teriparatide (Forteo\u2122) for the treatment of osteoporosis. \u3008http:\/\/www.rheumatology.org\/Publications\/Hotline\/Teriparatide\u3009 (accessed 30.07.14)."},{"key":"10.1016\/j.ejphar.2016.02.053_bib3","unstructured":"Amgen Ilt, 2014. Romosozumab clinical trials. \u3008www.amgen.com\u3009 (accessed 01.01.14)."},{"issue":"9041","key":"10.1016\/j.ejphar.2016.02.053_bib4","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention trial research group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2016.02.053_bib5","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the fracture intervention trial long-term extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2016.02.053_bib6","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years' experience with alendronate for osteoporosis in postmenoupausal women","volume":"350","author":"Bone","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ejphar.2016.02.053_bib7","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0002-9343(00)00490-3","article-title":"A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF study group","volume":"109","author":"Chesnut","year":"2000","journal-title":"Am J. Med."},{"issue":"18","key":"10.1016\/j.ejphar.2016.02.053_bib8","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.ejphar.2016.02.053_bib9","unstructured":"Clinical Trials, 2014. \u3008www.clinicaltrials.gov\u3009 (accessed October 30.10.14)."},{"issue":"2","key":"10.1016\/j.ejphar.2016.02.053_bib10","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/jbmr.1542","article-title":"Bisphosphonate therapy for osteoporosis: the long and short of it","volume":"27","author":"Compston","year":"2012","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.ejphar.2016.02.053_bib11","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/1759720X13490860","article-title":"Odanacatib in postmenopausal women with low bone mineral density: a review of current clinical evidence","volume":"5","author":"Cristiano","year":"2013","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"10.1016\/j.ejphar.2016.02.053_bib12","doi-asserted-by":"crossref","unstructured":"S.R. Cummings, J. San Martin, M.R. McClung, Denosumab for prevention of fractures in postmenopausal women with osteoporosis N. Engl. J. Med. 361 8 2009 756 765 (Erratum in: N Engl J Med. 2009;361[19]:1914). (b) S.R. Cummings, J. San Martin, M.R. McClung, N Engl J Med 361, 19 2009, 1914, (Erratum).","DOI":"10.1056\/NEJMx090058"},{"key":"10.1016\/j.ejphar.2016.02.053_bib13","first-page":"107","article-title":"Bisphosphonate drug holiday: who, when and how long","volume":"5","author":"Diab","year":"2013"},{"key":"10.1016\/j.ejphar.2016.02.053_bib14","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.bone.2013.09.023","article-title":"Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review","volume":"58","author":"Eriksen","year":"2014","journal-title":"Bone"},{"issue":"7","key":"10.1016\/j.ejphar.2016.02.053_sbref12","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple outcomes of raloxifene evaluation (MORE) investigators","volume":"18","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.ejphar.2016.02.053_sbref13","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1001\/jama.282.22.2124","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2016.02.053_bib16","unstructured":"European Medicines Agency, 2014. \u3008http:\/\/www.ema.europa.eu\u3009 (accessed 09.07.14)."},{"key":"10.1016\/j.ejphar.2016.02.053_bib17","unstructured":"FDA webpage, 2014. (Available at): \u3008http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM214385.pdf\u3009 (accessed 09.07.14)."},{"issue":"4","key":"10.1016\/j.ejphar.2016.02.053_bib18","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1210\/jc.2009-1703","article-title":"Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis","volume":"95","author":"Finkelstein","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2016.02.053_bib19","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00223-010-9420-x","article-title":"Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate and denosumab) on bone quality: a systematic review","volume":"87","author":"Gallacher","year":"2010","journal-title":"Calcif. Tissue Int."},{"issue":"6","key":"10.1016\/j.ejphar.2016.02.053_bib20","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.bone.2011.08.015","article-title":"Effects of one year daily teriparatide treatment on trabecular bone material properties in postmenopausal osteoporotic women previously treated with alendronate or risedronate","volume":"49","author":"Gamsjaeger","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.ejphar.2016.02.053_bib21","doi-asserted-by":"crossref","unstructured":"J. Gonz\u00e1lez Mac\u00edas, N. Gua\u00f1abens Gay, C. G\u00f3mez Alonso, L. Del R\u00edo Barquero, M. Mu\u00f1oz Torres, M. Delgado, L. P\u00e9rez Edo, B. D\u00edaz L\u00f3pez, E. J\u00f3dar Gimeno, F. Hawkins Carranza (Comit\u00e9de Redacci\u00f3n, en representaci\u00f3n del Comit\u00e9de Expertos de la SEIOMM para la elaboraci\u00f3n de las Gu\u00edas), 2008. Gu\u00edas de pr\u00e1ctica cl\u00ednica en la osteoporosis posmenop\u00e1usica, glucocorticoidea y del var\u00f3n. Sociedad Espa\u00f1ola de Investigaci\u00f3n \u00d3sea y del Metabolismo Mineral (SEIOMM). \u3008www.seiomm.org\u3009.","DOI":"10.1016\/S0014-2565(08)71780-6"},{"key":"10.1016\/j.ejphar.2016.02.053_bib22","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/PL00004148","article-title":"Worldwide projections for HIP fracture","volume":"7","author":"Gullberg","year":"1997","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.ejphar.2016.02.053_bib23","unstructured":"International Osteoporosis Foundation. \u3008http:\/\/www.iofbonehealth.org\u3009 (accessed 30.07.14)."},{"issue":"8","key":"10.1016\/j.ejphar.2016.02.053_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.70","article-title":"clerostin and the Regulation of Bone Formation: Effects in Hip Osteoarthritis and Femoral Neck Fracture","volume":"25","author":"Power","year":"2010","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.ejphar.2016.02.053_bib25","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.bone.2004.03.024","article-title":"A meta-analysis of previous fracture and subsequent fracture risk","volume":"35","author":"Kanis","year":"2004","journal-title":"Bone"},{"issue":"9","key":"10.1016\/j.ejphar.2016.02.053_bib26","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S1701-2163(15)30489-8","article-title":"Osteoporosis in menopause","volume":"36","author":"Khan","year":"2014","journal-title":"J. Obstet. Gynaecol. Can."},{"issue":"1","key":"10.1016\/j.ejphar.2016.02.053_bib27","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bone.2006.07.015","article-title":"A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in An acute model of elevated bone turnover in vivo in monkeys","volume":"40","author":"Kumar","year":"2007","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.ejphar.2016.02.053_bib28","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1359\/JBMR.0301240","article-title":"Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study","volume":"19","author":"Larsen","year":"2004","journal-title":"J. Bone Miner. Res."},{"issue":"18","key":"10.1016\/j.ejphar.2016.02.053_bib29","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after HIP fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N. Eng. J. Med."},{"key":"10.1016\/j.ejphar.2016.02.053_bib30","first-page":"CD004143","article-title":"Long term Hormone therapy for perimenopausal and postmenopausal women","volume":"7","author":"Marjoribanks","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejphar.2016.02.053_bib31","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s00223-004-0286-7","article-title":"Seven years of treatment with risendronate in women with postmenopausal osteoporosis","volume":"75","author":"Mellstom","year":"2004","journal-title":"Calif. Tissue Int."},{"key":"10.1016\/j.ejphar.2016.02.053_bib32","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s001980050218","article-title":"Vertebral fractures predict subsequent fractures","volume":"10","author":"Melton","year":"1999","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.ejphar.2016.02.053_bib33","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1007\/s00198-011-1773-0","article-title":"Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long term extension study","volume":"23","author":"Miller","year":"2012","journal-title":"Osteoporos. Int."},{"issue":"2","key":"10.1016\/j.ejphar.2016.02.053_bib34","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2165\/00024677-200403020-00006","article-title":"Calcitonin therapy in osteoporosis","volume":"3","author":"Mu\u00f1oz-Torres","year":"2004","journal-title":"Treat. Endocrinol."},{"key":"10.1016\/j.ejphar.2016.02.053_bib35","unstructured":"National Osteoporosis Foundation, 2014. Clinician's guide to prevention and treatment of osteoporosis. \u3008http:\/\/nof.org\/files\/nof\/public\/content\/file\/2610\/upload\/895.pdf\u3009 (accessed 09.07.14)."},{"issue":"19","key":"10.1016\/j.ejphar.2016.02.053_bib36","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ejphar.2016.02.053_bib37","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1185\/03007990902790993","article-title":"Teripatide vertebral fracture risk reduction determined by quantitative and qualitative radiographic assessment","volume":"25","author":"Pervhal","year":"2009","journal-title":"Curr. Med. Res. Opin."},{"issue":"6","key":"10.1016\/j.ejphar.2016.02.053_bib38","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/art.23461","article-title":"Effects of long-term strontium ranelate treatment on the risk of non-vertebral and vertebral fractures in postmenopausal osteoporosis: results of a five-years, randomized, placebo-controlled trial","volume":"58","author":"Reginster","year":"2008","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.ejphar.2016.02.053_bib39","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral efficacy with risedronate therapy (VERT) study group","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos. Int."},{"issue":"3","key":"10.1016\/j.ejphar.2016.02.053_bib40","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1016\/j.jaad.2010.11.033","article-title":"Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib","volume":"66","author":"R\u00fcnger","year":"2012","journal-title":"J. Am Acad. Dermatol."},{"key":"10.1016\/j.ejphar.2016.02.053_bib41","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/jbmr.11","article-title":"Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial","volume":"25","author":"Schwartz","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.ejphar.2016.02.053_bib42","unstructured":"SEIOMM, 2015. Guias de pr\u00e1ctica cl\u00ednica en la osteoporosis post-menop\u00e1usica, glucocorticoidea y del var\u00f3n. SEIOMM 2014. \u3008http:\/\/www.seiomm.org\/\u3009 (accessed 18.07.15)."},{"issue":"2","key":"10.1016\/j.ejphar.2016.02.053_bib43","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S8756-3282(02)00946-8","article-title":"Long-term efficacy of risendronate: a 5-years placebo-controlled clinical experience","volume":"32","author":"Sorensen","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.ejphar.2016.02.053_bib44","doi-asserted-by":"crossref","DOI":"10.1007\/s11657-011-0060-1","article-title":"Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA)","author":"Str\u00f6m","year":"2011","journal-title":"Arch Osteoporos"},{"key":"10.1016\/j.ejphar.2016.02.053_bib45","article-title":"Romosozumab and blosozumab: alternative drugs of mechanical strain-related stimulus toward a cure for osteoporosis","volume":"21","author":"Sugiyama","year":"2015","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ejphar.2016.02.053_bib46","first-page":"3109","article-title":"Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III osteoporosis treatment study group","volume":"85","author":"Tonino","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2016.02.053_bib47","unstructured":"M. Trapero-Bertr\u00e1n, R. Puig-Peir\u00f3 and L. Pellis\u00e9, 2012. Systematic Review of eConomic Evaluations done from Treatments used for Fracture Prevention in Post-menopausal Osteoporotic Women. Pompeu Fabra University.\u00a0Updated from 2008 to 2012. 26 Nov, 2012."},{"key":"10.1016\/j.ejphar.2016.02.053_bib48","unstructured":"World Health Organization, 1994. \u3008http:\/\/www.who.int\/nutrition\/topics\/5_population_nutrient\/en\/index25.html\u3009 (accessed 30.07.14)."},{"key":"10.1016\/j.ejphar.2016.02.053_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bone.2014.04.023","article-title":"Effects of eight-month treatment with ONO-5334, a cathepsin K inhibitor, on bone metabolism, strength and microstructure in ovariectomized cynomolgus monkeys","volume":"65","author":"Ochi","year":"2014","journal-title":"Bone"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429991630098X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429991630098X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T02:21:31Z","timestamp":1567650091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001429991630098X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":50,"alternative-id":["S001429991630098X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2016.02.053","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatments for post-menopausal osteoporotic women, what\u2019s new? How can we manage long-term treatment?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2016.02.053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}